3-Dimensional coculture of breast cancer cell lines with adipose tissue-Derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection labeling technology
/in Breast Cancer, International Publications, Newcastle Disease VirusA Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
/in Colorectal Cancer, Dendritic Cells, International PublicationsDendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsCurrent and emerging immunotherapeutic approaches for biliary tract cancers
/in Dendritic Cells, Gallbladder Cancer, International PublicationsOncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy
/in Glioblastoma, International Publications, Newcastle Disease VirusImmunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
/in Brain Tumors in Children, Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease VirusDendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer
/in Dendritic Cells, International Publications, Ovarian CancerDendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
/in Dendritic Cells, International PublicationsBreast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
/in Breast Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer